History, Development, and Current Status of Post-PharmD Industry Fellowship Programs at Northeastern University



Michael Silberstein, PhDa; John R. Reynolds, PharmDb

^{a.} Pharmacy Student (P4 year), ^{b.} Professor Emeritus School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA

Introduction


- Northeastern University School of Pharmacy and Pharmaceutical Sciences post-PharmD fellowship program was founded in 2012.
- In 2022-2023 (i.e., the year that this study occurred), the program had 52 (28 first-year and 24 second-year) fellows spanning 15 pharmaceutical companies. In 2023-2024, the program added 38 incoming first-year fellows (27% increase).
- The fellowships provide opportunities for graduates to contribute to the operations and pharmaceutical product development within the biotechnology industry.
- The fellowships are perceived to have mutually beneficial aspects relating to the fellows and the companies.
- Primary Goal of Study: To describe the development and assess the status of the Northeastern University fellowship program from the perspectives of various program stakeholders.


Primary Participants:

- Post-PharmD industry fellows
- Liaisons from partner biotechnology companies
- Northeastern University faculty/staff principals

Methods

Surveying/Interviewing Methods






Participation

- Ninety-three percent (26/28) of first-year fellows and 25% (6/24) of second-year fellows, respectively participated (**Figure 1**). (Note: Since responses to all questions were optional, not all 32 participants responded to every question).
- Eight out of twelve (75%) company liaisons also participated.

Figure 2 - Fellows' impression regarding whether they had a strong impact in the work/operations within their company (n = 31) 30 25 40 415 40 50 64.5 % O % 0 % 0 % Strongly Disagree Disagree Agree Strongly Agree

Figure 3 - Fellows' impression regarding whether they had a strong impact within the Northeastern University School of Pharmacy and Pharmaceutical Sciences community (n = 31)




School Bloom

Northeastern University Bouvé College of Health Sciences

School of Pharmacy and Pharmaceutical Sciences

Table 1 - Summary of SWOT analysis reported by Northeastern School of Pharmacy and Pharmaceutical Science faculty/staff coordinators



Faculty/staff principals performed a Strengths / Weaknesses / Opportunities / Threats (SWOT) analysis of the program (**Table 1**). This analysis highlighted distinct stabilizing and destabilizing aspects that affect the program's overall cohesiveness, camaraderie and continuity.

For example, overall program growth relies upon the following interplay of external factors:

- Companies on a growth surge may be more likely to include fellows on novel projects
- Fellow involvement in recruitment activities and committees
- Companies at risk of being purchased by larger and more established companies, eliminating specific fellowship opportunities
- Premature departures of fellows

Results

- Every responding fellow reported an impression of making a strong impact in the work/operations within the partner company. (Figure 2)
- Eighty-one percent of surveyed fellows agreed that their impact within the university is strong. (Figure 3)
- Seven of the eight interviewed company liaisons stated that the fellows exhibited distinct leadership qualities.
- According to both fellows and company liaisons, the most important qualities that signified a successful fellowship included:
- Ability to effectively manage a team while overseeing a project from start to finish
- Attaining a position at the sponsored or similar company upon fellowship completion
- Building a growing network while enhancing communication skills, people skills, and presentation skills.

Study Limitations

- Under-sampled second-year fellows
- Only single (rather than multiple) surveying opportunity per individual
- Overemphasis on consensus outcomes (vs. singletons)

Conclusion

• Findings reveal that the fellowships are in an auspicious stage, with growth and expansion expected as we move into our second decade of partnerships.